LigaChemBio Sciences Information

Founded in 2006 and headquartered in Daejeon, South Korea, LigaChem Biosciences (LCB) is a clinical-stage biopharmaceutical company dedicated to developing next-generation cancer therapies — led by ADC innovation and expanding into new modalities to address unmet patient needs. Our proprietary ADC platform ConjuAll™ integrates site-specific conjugation, a patented β-Glucuronide Linker, and novel payload technology to overcome the core limitations of conventional ADCs: linker instability, insufficient tumor selectivity, and payload resistance. Clinically validated across 5 ADCs in clinical stage and honored at the World ADC Awards for multiple consecutive years, ConjuAll™ is one of the most proven ADC platforms in the industry. To date, we have closed 15 ADC-related deals totaling over $8.7B in disclosed value — with partners across the U.S., Europe, and Asia. Powered by open innovation, we combine our proprietary technologies with the world's best expertise — creating scientific synergy that accelerates therapies from discovery to patients, faster. For additional information, please visit www.ligachembio.com